Study Finds No Advantage of Biomarker-Based Risk Scores in Personalizing Atrial Fibrillation Treatment
A recent study reveals that biomarker-based risk scores do not improve outcomes in personalized atrial fibrillation care compared to traditional guidelines, highlighting the need for further research in treatment customization.
Recent research presented at ESC Congress 2025 has concluded that using biomarker-based risk scores to tailor treatment strategies in patients with atrial fibrillation (AF) does not lead to improved clinical outcomes compared to standard guideline-based care. The study, a large registry-based randomized trial conducted across 39 Swedish sites, investigated whether incorporating biomarker scores like ABC-AF-stroke and ABC-AF-bleeding into treatment decisions would reduce the incidence of stroke and death.
Patients eligible for the trial included adults diagnosed with AF, regardless of whether they were on oral anticoagulant (OAC) therapy. Participants were randomized into two groups: a treatment arm guided by individual risk scores and recommendations, and a control group managed under usual clinical practice without biomarker data. Although the intervention successfully increased OAC use broadly, the primary outcome—composite of stroke or death—occurred at similar rates in both groups, around 3.2/100 patient-years.
The trial also found no significant differences in the rates of stroke, death, or major bleeding between the two arms over a median follow-up of 2.6 years. Despite the promising validation of these biomarker scores in previous studies, the results suggest that their implementation for personalized treatment did not provide additional benefit in this population. Notably, the trial was prematurely terminated due to safety concerns, and the event rates were lower than expected, leading to an underpowered study.
Lead researcher Professor Jonas Oldgren emphasized that further prospective testing is essential before integrating new risk stratification tools into routine AF management. Overall, this study underscores the importance of rigorous validation of precision medicine approaches and suggests that current standard care remains effective for stroke prevention in AF patients.
Source: https://medicalxpress.com/news/2025-09-benefit-biomarker-based-scores-personalize.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advancements in Machine Learning Enable Accurate Dengue Fever Predictions
Innovative machine learning models can forecast dengue fever outbreaks with 80% accuracy, aiding health officials in outbreak preparedness and response.
West Coast States Establish Their Own COVID, Flu, and RSV Vaccination Guidelines
California, Hawaii, Oregon, and Washington have issued new vaccine guidance, promoting broader COVID, flu, and RSV vaccination efforts aligned with scientific evidence, challenging federal CDC recommendations.
Innovative Genetic Tools Aid Precision Intervention in Brain Disease Research
Researchers have developed a comprehensive toolkit of over 1,000 engineered viral vectors that allow precise targeting of specific brain cells, paving the way for advanced therapies for neurological disorders.
Groundbreaking Clinical Trial Confirms Effectiveness and Safety of New Treatments for Bubonic Plague
A groundbreaking clinical trial confirms the safety and effectiveness of oral ciprofloxacin as a treatment for bubonic plague, promising easier and more affordable management in remote areas. The study, conducted in Madagascar, marks a historic milestone in plague research and treatment.